Search by Drug Name or NDC
NDC 51079-0923-20 Carbidopa and Levodopa 50; 200 mg/1; mg/1 Details
Carbidopa and Levodopa 50; 200 mg/1; mg/1
Carbidopa and Levodopa is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Mylan Institutional Inc.. The primary component is CARBIDOPA; LEVODOPA.
MedlinePlus Drug Summary
The combination of levodopa and carbidopa is used to treat the symptoms of Parkinson's disease and Parkinson's-like symptoms that may develop after encephalitis (swelling of the brain) or injury to the nervous system caused by carbon monoxide poisoning or manganese poisoning. Parkinson's symptoms, including tremors (shaking), stiffness, and slowness of movement, are caused by a lack of dopamine, a natural substance usually found in the brain. Levodopa is in a class of medications called central nervous system agents. It works by being converted to dopamine in the brain. Carbidopa is in a class of medications called decarboxylase inhibitors. It works by preventing levodopa from being broken down before it reaches the brain. This allows for a lower dose of levodopa, which causes less nausea and vomiting.
Related Packages: 51079-0923-20Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Levodopa and Carbidopa
Product Information
| NDC | 51079-0923 |
|---|---|
| Product ID | 51079-923_0e0d2dec-f824-807f-e063-6394a90ad142 |
| Associated GPIs | 73209902100420 |
| GCN Sequence Number | 016043 |
| GCN Sequence Number Description | carbidopa/levodopa TABLET ER 50MG-200MG ORAL |
| HIC3 | H6A |
| HIC3 Description | ANTIPARKINSONISM DRUGS,OTHER |
| GCN | 62591 |
| HICL Sequence Number | 013894 |
| HICL Sequence Number Description | CARBIDOPA/LEVODOPA |
| Brand/Generic | Generic |
| Proprietary Name | Carbidopa and Levodopa |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | carbidopa and levodopa |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 50; 200 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | CARBIDOPA; LEVODOPA |
| Labeler Name | Mylan Institutional Inc. |
| Pharmaceutical Class | Amino Acids, Aromatic [CS], Aromatic Amino Acid [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA075091 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 51079-0923-20 (51079092320)
| NDC Package Code | 51079-923-20 |
|---|---|
| Billing NDC | 51079092320 |
| Package | 100 BLISTER PACK in 1 CARTON (51079-923-20) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (51079-923-01) |
| Marketing Start Date | 1999-12-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.20937 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | CARBIDOPA-LEVO ER 50-200 TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |